Announced
Completed
Financials
Tags
Private
Acquisition
Completed
Friendly
Biotechnology
research company
clinical development
United Kingdom
Majority
Single Bidder
Synopsis
LabCorp, a global life sciences company, completed the acquisition of Chiltern, a provider of clinical services and solutions in a variety of therapeutic areas, for $1.2bn. “This acquisition strengthens our position as a leading life sciences company that delivers innovative diagnostics and drug development solutions to improve health and improve lives. Our acquisition of Covance has demonstrated the value of combining diagnostic and CRO capabilities, expertise, data and leadership. The addition of Chiltern furthers our strategy and will provide us with enhanced capabilities across a broader client base as we continue to innovate and grow,” David P. King, LabCorp Chairman and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.